Related Experiment Video
Updated: Jan 9, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.7K
Advanced Pulmonary Sarcoidosis: Treatment and Monitoring
Gioele Castelli1,2, Jessica Raja1, Sam Banisadr1
1Interstitial Lung Disease Unit, Royal Brompton Hospital Part of Guy's and St Thomas's Foundation Trust, London SW3 6NP, UK.
Diagnostics (Basel, Switzerland)
|December 11, 2025
Summary
Advanced pulmonary sarcoidosis (APS) detection is vital for managing risks like respiratory failure and pulmonary hypertension. Early identification and monitoring of APS are key to improving patient outcomes and reducing mortality in this multi-system inflammatory disease.
Area of Science:
- Pulmonology
- Rheumatology
- Immunology
Background:
- Sarcoidosis is a multi-system inflammatory disease with significant clinical challenges.
- Advanced pulmonary sarcoidosis (APS) is linked to severe outcomes, including respiratory failure, pulmonary hypertension (PH), and infections.
- APS contributes to the majority of sarcoidosis-related mortality.
Purpose of the Study:
- To define APS by identifying prognostic factors in pulmonary sarcoidosis.
- To outline monitoring strategies for disease progression and complications like PH.
- To review current treatment regimens for APS, including antifibrotic therapies.
Main Methods:
- Literature review focusing on prognostic factors in pulmonary sarcoidosis.
- Analysis of monitoring strategies for APS progression and complications.
- Evaluation of treatment options for APS, including emerging antifibrotic agents.
Main Results:
- Prognostic factors for defining and identifying APS have been established.
- Effective monitoring strategies can detect disease progression and complications such as PH.
- Treatment options for APS are evolving, with antifibrotic therapy showing promise for select patients.
Conclusions:
- Early and consistent detection of APS is critical for patient management.
- Regular monitoring is essential for timely intervention against disease progression and complications.
- Optimized treatment strategies, including antifibrotics, are crucial for improving outcomes in APS.
Related Concept Videos
01:28Pulmonary Tuberculosis V
523
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
523
01:28Pneumonia IV: Management
726
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
726
01:27Pneumothorax-II
852
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
852
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
01:26Acute Coronary Syndrome V: Nursing Management
247
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
247
01:26COPD: Management Using Bronchodilators and Corticosteroids
700
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
700